B. E. Johnson

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).

Mark G. Kris, B. E. Johnson, D J Kwiatkowski et al. · Journal of Clinical Oncology · 2011 · 213 citations

Surgical Oncology, Cancer Pathology, Cancer Management +18

Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

Fairooz F. Kabbinavar, V.A. Miller, B. E. Johnson et al. · Journal of Clinical Oncology · 2010 · 110 citations

Cancer Management, Pathology, First-line Treatment +17

Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1^st-line treatment in patients with NSCLC

B. E. Johnson, Pingli Ma, Howard West et al. · Journal of Clinical Oncology · 2005 · 43 citations

Oncology, Medicine, Cancer Management +10

Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.

Gail L. Shaw, Adi F. Gazdar, Ruby Phelps et al. · PubMed · 1993 · 41 citations

Pathology, Pharmacotherapy, Metronomic Chemotherapy +16

A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC

John V. Heymach, B. E. Johnson, Jacqui Rowbottom et al. · Journal of Clinical Oncology · 2005 · 41 citations

Oncology, Clinical Therapeutic, Zd6474 300 +10